Scott Antonia

3 ta ish

Duke University

1. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

   Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer +27

   MaqolaOAOchiq kirish20123 iqtibos

   ABIABI:AkademIndex/2026.other.132162

2. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

   Julie R. Brahmer, Karen L. Reckamp, Paul Baas +22

   MaqolaOAOchiq kirish20153 iqtibos

   ABIABI:AkademIndex/2026.other.170111

3. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial

   Ben Creelan, Chao Wang, Jamie K. Teer +23

   Maqola20213 iqtibos

   ABIABI:AkademIndex/2026.other.296890